Campbell David Alan's Form 4 filing
Janux Therapeutics, Inc. (JANX) · filed Dec 27, 2024
- Accession no.
- 0001415889-24-030211
- Filed
- Dec 27, 2024
- Trade date
- Dec 24, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.40M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Campbell David AlanCIK 0001864158 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 24, 2024 | Common Stock | SSaleDisposed | −25,000 | $56.19F2 | −$1,404,750 | 217,054 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The weighted average sale price for the transaction reported was $56.1922 and the range of prices were between $56.00 and $56.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.